A detailed history of Hudson Bay Capital Management LP transactions in Legend Biotech Corp stock. As of the latest transaction made, Hudson Bay Capital Management LP holds 55,000 shares of LEGN stock, worth $2.21 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
55,000
Holding current value
$2.21 Million
% of portfolio
0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$39.5 - $57.22 $2.17 Million - $3.15 Million
55,000 New
55,000 $2.44 Million
Q4 2023

Feb 14, 2024

BUY
$57.25 - $69.74 $2.86 Million - $3.49 Million
50,000 New
50,000 $3.01 Million
Q3 2022

Nov 14, 2022

SELL
$38.15 - $57.1 $46.2 Million - $69.2 Million
-1,211,350 Reduced 96.23%
47,500 $1.94 Million
Q2 2022

Aug 12, 2022

SELL
$33.54 - $55.0 $754,650 - $1.24 Million
-22,500 Reduced 1.76%
1,258,850 $69.2 Million
Q1 2022

May 16, 2022

SELL
$31.02 - $48.18 $18.5 Million - $28.7 Million
-595,000 Reduced 31.71%
1,281,350 $46.6 Million
Q4 2021

Feb 14, 2022

SELL
$41.14 - $56.98 $97,008 - $134,358
-2,358 Reduced 0.13%
1,876,350 $87.5 Million
Q3 2021

Nov 15, 2021

BUY
$35.31 - $50.56 $11,793 - $16,887
334 Added 0.02%
1,878,708 $95 Million
Q2 2021

Aug 16, 2021

SELL
$25.8 - $41.09 $7.45 Million - $11.9 Million
-288,900 Reduced 13.33%
1,878,374 $77.1 Million
Q1 2021

May 14, 2021

SELL
$23.55 - $32.4 $13.4 Million - $18.4 Million
-567,932 Reduced 20.76%
2,167,274 $62.9 Million
Q4 2020

Feb 12, 2021

SELL
$25.8 - $32.39 $2.34 Million - $2.93 Million
-90,600 Reduced 3.21%
2,735,206 $77 Million
Q3 2020

Nov 12, 2020

SELL
$27.5 - $39.61 $6.34 Million - $9.13 Million
-230,536 Reduced 7.54%
2,825,806 $84.2 Million
Q2 2020

Aug 12, 2020

BUY
$36.1 - $42.56 $110 Million - $130 Million
3,056,342 New
3,056,342 $122 Million

Others Institutions Holding LEGN

About Legend Biotech Corp


  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $6.73B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track This Portfolio

Track Hudson Bay Capital Management LP Portfolio

Follow Hudson Bay Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Hudson Bay Capital Management LP with notifications on news.